Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0IVGU)

• Drug Name: PLX7486 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DM0IVGU

Molecule-Related Drug Atlas

Drug(s) Targeting Tropomyosin-related kinase A (TrkA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[4]
Repotrectinib	DM9FB2T	Non-small-cell lung cancer	2C25	Approved	[2]
Larotrectinib	DM26CQR	Solid tumour/cancer	2A00-2F9Z	Approved	[5]
MIM-D3	DMZHN5B	Alzheimer disease	8A20	Phase 3	[6]
SNA-120	DMPN314	Plaque psoriasis	EA90.0	Phase 2	[7]
CT 327	DMQXL1T	Plaque psoriasis	EA90.0	Phase 2	[8]
ONO-7579	DMXLPYE	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
Altiratinib	DMUJCBT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
DS-6051	DM0RD4F	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
LOXO-195	DMDXFBJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

Drug(s) Targeting Macrophage colony-stimulating factor 1 receptor (CSF1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[11]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[2]
ARRY-382	DM0VGDC	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
BLZ-945	DMG1LVA	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[2]
Cabiralizumab	DMGE058	Pancreatic cancer	2C10	Phase 2	[12]
AMB-05X	DM958C5	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[13]
FPA-008	DM3ZN6Y	Autoimmune diabetes	5A10	Phase 1/2	[14]
DCC-3014	DMHW289	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
DCC-3014	DMHW289	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[15]
TPX-0022	DMC2IJN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]

Drug(s) Targeting Granulocyte colony-stimulating factor receptor (G-CSF-R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tbo-Filgrastim	DML6OE7	Neutropenia	4B00.0	Approved	[17]
Pegfilgrastim	DM7UP8X	Central nervous system neoplasm		Approved	[18]
Peg-G-CSF	DMBKWAF	Solid tumour/cancer	2A00-2F9Z	Phase 3	[19]
BLZ-945	DMG1LVA	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[19]
SBC-014	DMG1VXR	Neutropenia	4B00.0	Phase 2	[20]
AX-200	DMTAEMB	Cardiovascular disease	BA00-BE2Z	Phase 2	[21]
MAXY-G34	DMWLIPJ	Neutropenia	4B00.0	Phase 2	[22]
AMG 820	DMB6Q19	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
MK-6302	DMZUA5C	Neutropenia	4B00.0	Phase 1	[23]
PLX-5622	DMK4PWM	Autoimmune diabetes	5A10	Phase 1	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Granulocyte colony-stimulating factor receptor (G-CSF-R)	TTC70AJ	CSF3R_HUMAN	Inhibitor	[3]
Macrophage colony-stimulating factor 1 receptor (CSF1R)	TT7MRDV	CSF1R_HUMAN	Inhibitor	[2]
Tropomyosin-related kinase A (TrkA)	TTTDVOJ	NTRK1_HUMAN	Inhibitor	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038879)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] National Cancer Institute Drug Dictionary (drug id 747694).
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [6] Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
• [9] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [10] National Cancer Institute Drug Dictionary (drug id 766123).
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Clinical pipeline report, company report or official report of AmMax Bio
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
• [16] Clinical pipeline report, company report or official report of Turning Point Therapeutics.
• [17] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [18] Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
• [20] A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009; 9: 2.
• [21] Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke. 2013 Oct;44(10):2681-7.
• [22] Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys. 2014 Jan;106(1):21-38.
• [23] Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636.
• [24] Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Mol Med. 2012; 18(1): 519-527.